Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)

American Heart Journal

Volumn 161, Issue 3, 2011, Pages 581-589

  Kukuła, Krzysztof ^a   Chojnowska, Lidia ^a   Da̧browski, MacIej ^a   Witkowski, Adam ^a   Chmielak, Zbigniew ^a   Skwarek, Mirosław ^a   Ka̧dziela, Jacek ^a   Teresińska, Anna ^a   Małecki, MacIej ^b   Janik, Przemysław ^b   Lewandowski, Zbigniew ^c   Kłopotowski, Mariusz ^a   Wnuk, Jacek ^a   Ruzyłło, Witold ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PLACEBO; PLASMID VECTOR; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT RESPONSE; WORKLOAD;

AGED; EXERCISE TEST; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMIDS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952447660     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.11.023     Document Type: Article

References (36)

1. Epstein S.E., Fusch S., and Zhou Y.F. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards J Cardiovasc Res 49 2001 532 542 (Pubitemid 32146416)
2. Henry T.D., Annex B.H., and McKendall G.R. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis Circulation 107 2003 1359 1365 (Pubitemid 36350732)
3. Landau C., Jacobs A.K., and Haudenschild C.C. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia Am Heart J 129 1995 924 931
4. Banai S., Jaklitsch M.T., and Shou M. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs Circulation 89 1994 2183 2189 (Pubitemid 24142797)
5. Kornowski R., Hong M.K., and Haudenschild C. Feasibility and safety of percutaneous direct myocardial revascularization using Biosense system in porcine heart Coronary artery disease 9 1998 535 540 (Pubitemid 28517598)
6. Rissanen T.T., and Yla-Herttuala S. Current status of cardiovascular gene therapy Mol Ther 15 2007 1233 1247 (Pubitemid 46965318)
7. Sarkar N., Ruck A., and Kallner G. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy J Int Med 250 2001 373 381 (Pubitemid 32990045)
8. Joergensen E, Kastrup J, Thuesen L, et al. Direct percutaneous transluminal intramyocardial injection therapy. Circulation 2002;(Suppl II);106:3236, p.II-656
9. Vale P.R., Losordo D.W., and Milliken C.E. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia Circulation 103 2001 2138 2143 (Pubitemid 32458322)
10. Grines C.L., Watkins M.W., and Helmer G. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris Circulation 105 2002 1291 1297 (Pubitemid 34260418)
11. Grines C.L., Watkins M.W., and Mahmarian J.J. A randomized, double-blind, placebo-controlled trial of Ad 5 FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina J Am Coll Cardiol 42 2003 1339 1347 (Pubitemid 37267270)
12. Grines C.L. The AGENT clinical trials programme Eur Heart J 6 Suppl E 2004 E18 E23
13. Hedman M., Hartikainen J., and Syvanne M. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia. Phase II results of the Kuopio angiogenesis trial (KAT) Circulation 107 2003 2677 2683 (Pubitemid 36667240)
14. Losordo D.W., Vale P.R., and Hendel R.C. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia Circulation 105 2002 2012 2018 (Pubitemid 34465261)
15. Kastrup J., Jorgensen E., and Ruck A. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial J Am Coll Cardiol 45 2005 982 988 (Pubitemid 40432426)
16. Kastrup J., Jjorgensen E., and Fuchs S. A randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of advegf121 Biobypass gene therapy in patients with refractory advanced coronary artery disease The Nova trial., oral presentation; 14th World Congress of Heart Disease, Toronto 2008
17. Stewart D.J., Kutryk M.J., and Fitchett D. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial Mol Ther 17 2009 1109 1115
18. Henry T.D., Grines C.L., and Watkins M.W. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials J Am Coll Cardiol 50 2007 1038 1046 (Pubitemid 47354223)
19. Stewart D.J., Hilton J.D., and Arnold J.M. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment Gene Ther 13 2006 1503 1511 (Pubitemid 44574158)
20. Goto F., Goto K., and Weindel K. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels Lab Invest 69 1993 508 517 (Pubitemid 24004487)
21. Kukula K., Dabrowski M., and Chojnowska L. Theoretical base and investigational plan of the VIFCAD study-gene therapy for refractory coronary artery disease in no-option patients using transendocardial bicistronic VEGF/FGF plasmid injections Post Kardiol Interw 2 2006 116 123
22. Malecki M., Przybyszewska M., and Janik P. Construction of a bicistronic proangiogenic expression vector and its application in the experimental angiogenesis in vivo Acta Biochim Pol 50 2003 875 882 (Pubitemid 38623820)
23. Malecki M., Swoboda P., and Jastrzȩbski Z. In vivo study of angiogenic plasmid preparations-the bicistronic plasmid as a new type of drug for vascular diseases Acta Pol Pharm 61 2004 289 295 (Pubitemid 40188864)
24. Malecki M., Przybyszewska M., and Janik P. In vitro and in vivo study of the expression vector encoding vascular endothelial growth factor Arch Immunol Ther Exp 49 2001 243 246 (Pubitemid 32708526)
25. Jastrzebski Z., Malecki M., and Janik P. Badanie stopnia oczyszczenia z endotoksyn bakteryjnych preparatów plazmidowych przygotowanych dla potrzeb angiogennej terapii genowej Farm Pol 59 2003 171 175
26. Cerqueira M.D., Weissman N.J., and Dilsizian V. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association Circulation 105 2002 539 542 (Pubitemid 34262671)
27. Hachamovitch R., Hayes S.W., and Friedman J.D. Comparison of the short-term survival benefit associated with revascularisation compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography Circulation 107 2003 2900 2906 (Pubitemid 36736630)
28. Berman D.S., Abidov A., and Kang X. Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion SPECT interpretation J Nucl Cardiol 11 2004 414 423 (Pubitemid 39107079)
29. Germano G., Kiat H., and Kavanagh P.B. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT J Nucl Med 36 1995 2138 2147
30. Teresińska A., Wnuk J., and Konieczna S. Verification of the left ventricular ejection fraction from gated myocardial perfusion studies (GSPECT) Kardiol Pol 63 2005 465 475 (Pubitemid 44283982)
31. Altman D.G. Practical statistics for medical research, London 1991
32. Henry T.D., Satran D., and Campbell A.R. Long-term mortality in patients with refractory angina J Am Coll Cardiol 51 2008 A227
33. Nikol S. Viral or non-viral angiogenesis gene transfer-new answers to old questions Cardiovasc Res 73 2007 443 445 (Pubitemid 46073958)
34. Ahn A., Frishman W.H., and Gutwein A. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I Cardiol Rev 16 2008 163 171
35. Allera-Moreau C., Delluc-Clavières A., and Castano C. Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscle BMC Biotechnol 7 2007 74
36. Li J., Menzel C., and Meier D. A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies J Immunol Methods 318 2007 113 124 (Pubitemid 46026813)